SYSTEMIC SCLEROSIS (SSC)

This study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…

This early-stage trial is testing a new treatment called CT1190B CAR-T cell therapy for people with moderate to severe lupus or scleroderma that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and potentially calm the ove…

This early-stage trial tests whether specially engineered immune cells (CAR-T cells) can safely treat children with severe systemic sclerosis that hasn't improved with standard drugs. Twelve participants will receive a single infusion of these cells, and doctors will monitor chan…

This early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…

This early-stage trial is testing a new type of CAR-T cell therapy in 11 children with severe, treatment-resistant rheumatic diseases like juvenile dermatomyositis and arthritis. The therapy uses the child's own immune cells, modified to target two proteins (BCMA and CD70) on fau…

This early-phase trial tests a new drug called PRO-203, given as a single shot under the skin. First, healthy volunteers will check safety; then, people with systemic sclerosis (a rare autoimmune disease that hardens skin and organs) will receive the drug. The main goal is to see…

This study tests an experimental drug called efgartigimod PH20 SC in adults with systemic sclerosis, a disease that causes skin thickening and organ problems. About 81 participants will receive either the drug or a placebo as a shot under the skin for up to 48 weeks. Researchers …

This early-phase study tests a new treatment called OL-CD19-GDT, which uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and destroy faulty immune cells in people with severe systemic sclerosis or Sjögren's syndrome that has not responded to stan…

This early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…

This phase 2 trial tests a therapy called AlloNK, made from donor cord blood immune cells, combined with the drug rituximab. It aims to see if this combination is safe and can help people with severe forms of rheumatoid arthritis, Sjögren's disease, myositis, or scleroderma that …

This early-stage study tests the safety of a new drug called CC312 in up to 18 adults with autoimmune diseases like lupus or rheumatoid arthritis that haven't responded to standard treatments. CC312 is designed to help the body's immune cells target and destroy faulty B cells tha…

This early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…

This early-phase study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. The treatment uses a special injection to create CAR-T cells inside the body, which then target and dest…

This study tests a new drug called tibulizumab in 80 adults with systemic sclerosis, a disease that causes skin thickening and can affect internal organs. For the first 24 weeks, some participants get the drug and some get a placebo, then everyone can receive the drug for another…

This early-phase trial tests a new treatment called zamto-cel for people with severe lupus or scleroderma that hasn't improved with standard therapies. Zamto-cel uses a patient's own immune cells, modified to target and calm the overactive immune system. The main goal is to check…

This study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The goal is to see if it's safe and can control the d…

This early-stage study tests a new cell therapy called FT819 in people with moderate-to-severe autoimmune diseases like lupus, vasculitis, myositis, and scleroderma. The goal is to see if it is safe and can reduce disease activity by targeting the immune cells that cause the dama…

This early-stage study tests a new treatment called QT-219C, which uses specially engineered immune cells (CAR-T cells) to target and destroy faulty B cells that drive autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusion a…

This early-stage trial tests an experimental treatment called QEL-005 for people with two serious autoimmune conditions: diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis. QEL-005 is made from a patient's own white blood cells, which are genetically…

This study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…

This early-stage study tests a new treatment for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard therapies. The treatment uses specially engineered immune cells (CAR T-cells) from a healthy donor to target and potentially rese…

This early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…

This study is testing a new blood-based test that aims to predict which medication will work best for each person with an autoimmune rheumatic disease. Researchers will take a blood sample and use it to measure how a patient's immune cells respond to different drugs. If successfu…

This study compares three different diets to see which best reduces bloating and other gut symptoms in people with systemic sclerosis (scleroderma). Sixty participants will follow a low FODMAP diet, a gut-healing elimination diet, or a standard healthy-eating diet for six weeks, …

This study is testing a structured exercise program called BETY, which focuses on the whole person (body, mind, and social factors), in 48 children and adults with scleroderma. Participants will either do the BETY program for 3 months or follow a home exercise routine. The goal i…

This study tests whether a lotion containing 1% hemp extract (CBD) plus 10% urea can relieve itching, improve skin moisture, and help sleep in people with scleroderma. About 36 adults with chronic itching will use both the CBD lotion and a plain urea lotion at different times to …

This study tests if a person's own fat-derived cells can improve hand function in systemic sclerosis, a disease that causes skin thickening and stiffness. 48 adults with hand problems will either get injections of these cells into their fingers or receive standard care. The goal …

This study tests whether a wearable device called Apollo Neuro can help people with systemic sclerosis feel less tired and have fewer Raynaud's attacks. About 160 adults with the condition will use the device and report their symptoms through a phone app. The goal is to see if th…

This study tests whether injecting sodium thiosulfate directly into painful calcium deposits can shrink them and ease symptoms. It includes 20 adults with systemic sclerosis, dermatomyositis, or mixed connective tissue disease who have calcium buildup in skin or tendons. Particip…

This study looks at how scleroderma affects chewing and swallowing in both children and adults. Researchers will measure mouth opening, swallowing ability, and eating performance, and link these to patients' overall well-being. The goal is to find better ways to assess and suppor…

This study is testing whether artificial intelligence (AI) can better detect a serious lung condition called pulmonary arterial hypertension (PAH) in people with scleroderma. Researchers will compare AI algorithms to traditional screening methods in 350 patients across multiple h…

This study looks at how scleroderma affects physical performance and daily functioning in both children and adults. Researchers will use simple tests like walking, stair climbing, and sit-to-stand exercises to measure abilities. The goal is to find better ways to assess and manag…

This study aims to find a way to predict which cancer patients will experience side effects from immunotherapy. These side effects happen when the immune system attacks healthy tissues, similar to autoimmune diseases. Researchers will collect blood samples from 300 cancer patient…

This study is looking at how nutrition affects disease activity in people with rheumatic diseases like rheumatoid arthritis, lupus, and psoriatic arthritis. Researchers will measure the nutritional status of 460 participants using several different tools and compare it to how act…

This study follows about 70 people who have already received KYV-101, a CAR T-cell therapy, for autoimmune diseases like lupus and multiple sclerosis. Researchers will monitor participants for up to 15 years to track any delayed side effects, new cancers, or other health problems…

This study aims to translate and test a questionnaire called PASTUL, which helps people with scleroderma assess the thickness of their own skin. Researchers will enroll 50 adults with scleroderma to see if the Turkish version is reliable and accurate. The goal is to give patients…

This study aims to develop a better way to measure calcium deposits under the skin in people with scleroderma. Researchers will use CT scans and special software to see if these measurements match how patients report their symptoms. About 56 adults with scleroderma and calcium de…